Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
Roshini Claire Anthony, 20 hours ago

The presence of pulmonary arterial hypertension (PAH) in individuals with systemic sclerosis is associated with an increased mortality risk, a study from Singapore showed.

23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
09 Jan 2020
Acute ischaemic stroke patients who are current or recent smokers are at greater odds of having unfavourable functional outcomes 3 months after the index event, a study has found.

Enasidenib beneficial to certain elderly patients with IDH2-mutated AML

16 Dec 2019

Targeted treatment with enasidenib appears to be well tolerated in older adults with acute myeloid leukaemia (AML) harbouring an isocitrate dehydrogenase 2 (IDH2) mutation who are not fit for standard chemotherapy regimens, according to data from a phase I/II trial.

A total of 39 patients (median age, 77 years; 59 percent had antecedent haematologic disorder) received total enasidenib doses of 50–650 mg/day, administered orally in continuous 28-day treatment cycles.

Researchers obtained bone marrow biopsies and/or aspirates and peripheral blood samples at baseline, on day 1 of treatment cycle 2, every 28 days for the next 12 months and then every 56 days thereafter during enasidenib treatment.

The median number of enasidenib treatment cycles was 6.0 (range 1–35). Commonly reported treatment-related adverse events were indirect hyperbilirubinaemia (31 percent), nausea (23 percent), fatigue, and decreased appetite and rash (18 percent each).

Treatment-related grade 3–4 cytopoenia occurred in eight patients (21 percent), and none developed treatment-related high-grade infections.

There were 12 patients who achieved response (overall response rate, 30.8 percent, 95 percent confidence interval [CI], 17.0–47.6), including seven who showed complete remission (18 percent). The median duration of any response was not reached at a median follow-up of 8.4 months.

The median overall survival was 11.3 months (95 percent CI, 5.7–15.1) in the entire cohort and not reached in the subgroup of responders.

Being noncytotoxic and generally well tolerated with minimal drug interactions, enasidenib may prove beneficial to older patients with mutant-IDH2 AML when used in combination with other AML treatments, the researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
Roshini Claire Anthony, 20 hours ago

The presence of pulmonary arterial hypertension (PAH) in individuals with systemic sclerosis is associated with an increased mortality risk, a study from Singapore showed.

23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
09 Jan 2020
Acute ischaemic stroke patients who are current or recent smokers are at greater odds of having unfavourable functional outcomes 3 months after the index event, a study has found.